Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibody-mediated protection against Ebola virus
Erica Ollmann Saphire, Sharon L. Schendel, Bronwyn M. Gunn, et al.
Nature Immunology (2018) Vol. 19, Iss. 11, pp. 1169-1178
Open Access | Times Cited: 140

Showing 1-25 of 140 citing articles:

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Johanna K. Hansen, Alina Baum, Kristen E. Pascal, et al.
Science (2020) Vol. 369, Iss. 6506, pp. 1010-1014
Open Access | Times Cited: 1339
A human monoclonal antibody blocking SARS-CoV-2 infection
Chunyan Wang, Wentao Li, Dubravka Drabek, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 1124
Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
Egor P. Tchesnokov, Joy Y. Feng, Danielle P. Porter, et al.
Viruses (2019) Vol. 11, Iss. 4, pp. 326-326
Open Access | Times Cited: 588
Distinct Early Serological Signatures Track with SARS-CoV-2 Survival
Caroline Atyeo, Stephanie Fischinger, Tomer Zohar, et al.
Immunity (2020) Vol. 53, Iss. 3, pp. 524-532.e4
Open Access | Times Cited: 379
Correlates of protection against SARS‐CoV‐2 infection and COVID‐19 disease
David Goldblatt, Galit Alter, Shane Crotty, et al.
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 6-26
Open Access | Times Cited: 233
A human monoclonal antibody blocking SARS-CoV-2 infection
Chunyan Wang, Wentao Li, Dubravka Drabek, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 226
A rapid and label-free platform for virus capture and identification from clinical samples
Yin‐Ting Yeh, Kristen Gulino, YuHe Zhang, et al.
Proceedings of the National Academy of Sciences (2019) Vol. 117, Iss. 2, pp. 895-901
Open Access | Times Cited: 186
A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Tal Noy-Porat, Efi Makdasi, Ron Alcalay, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 150
SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months
Ania Wajnberg, Fatima Amanat, Adolfo Firpo, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 137
Viral vector vaccines
Naina McCann, Daniel O’Connor, Teresa Lambe, et al.
Current Opinion in Immunology (2022) Vol. 77, pp. 102210-102210
Open Access | Times Cited: 69
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV
Stefanie Ehrhardt, Matthias Zehner, Verena Krähling, et al.
Nature Medicine (2019) Vol. 25, Iss. 10, pp. 1589-1600
Open Access | Times Cited: 111
Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases
Edward B. Irvine, Galit Alter
Glycobiology (2020) Vol. 30, Iss. 4, pp. 241-253
Open Access | Times Cited: 107
Drug Discovery Strategies for SARS-CoV-2
Zeenat A. Shyr, Kirill Gorshkov, Catherine Z. Chen, et al.
Journal of Pharmacology and Experimental Therapeutics (2020) Vol. 375, Iss. 1, pp. 127-138
Open Access | Times Cited: 105
Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
Shuang Wang, Yun Peng, Rongjuan Wang, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 72
Exploiting the reverse vaccinology approach to design novel subunit vaccines against Ebola virus
Md. Asad Ullah, Bishajit Sarkar, Syed Sajidul Islam
Immunobiology (2020) Vol. 225, Iss. 3, pp. 151949-151949
Open Access | Times Cited: 69
Integration of mechanistic immunological knowledge into a machine learning pipeline improves predictions
Anthony Culos, Amy S. Tsai, Natalie Stanley, et al.
Nature Machine Intelligence (2020) Vol. 2, Iss. 10, pp. 619-628
Open Access | Times Cited: 69
Structure of the Inmazeb cocktail and resistance to Ebola virus escape
Vamseedhar Rayaprolu, Benjamin O. Fulton, Ashique Rafique, et al.
Cell Host & Microbe (2023) Vol. 31, Iss. 2, pp. 260-272.e7
Open Access | Times Cited: 27
Virus-Inspired Function in Engineered Protein Cages
Thomas G. W. Edwardson, Donald Hilvert
Journal of the American Chemical Society (2019) Vol. 141, Iss. 24, pp. 9432-9443
Closed Access | Times Cited: 57
Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients
Anwar M. Hashem, Abdullah Algaissi, Sarah A. Almahboub, et al.
Viruses (2020) Vol. 12, Iss. 12, pp. 1390-1390
Open Access | Times Cited: 55
Epitope profiling reveals binding signatures of SARS-CoV-2 immune response in natural infection and cross-reactivity with endemic human CoVs
Caitlin I. Stoddard, Jared Galloway, Helen Y. Chu, et al.
Cell Reports (2021) Vol. 35, Iss. 8, pp. 109164-109164
Open Access | Times Cited: 52
A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus
Bronwyn M. Gunn, Richard Lu, Matthew D. Slein, et al.
Immunity (2021) Vol. 54, Iss. 4, pp. 815-828.e5
Open Access | Times Cited: 51
Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11
Juliette Fédry, Daniel L. Hurdiss, Chunyan Wang, et al.
Science Advances (2021) Vol. 7, Iss. 23
Open Access | Times Cited: 48
Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients
Juan Manuel Carreño, Hala Alshammary, Gagandeep Singh, et al.
EBioMedicine (2021) Vol. 73, pp. 103626-103626
Open Access | Times Cited: 48
High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies
Meghan Garrett, Jared Galloway, Helen Y. Chu, et al.
Cell (2021) Vol. 184, Iss. 11, pp. 2927-2938.e11
Open Access | Times Cited: 41
Recombinant vaccines in 2022: a perspective from the cell factory
Marianna Teixeira de Pinho Favaro, Jan Atienza-Garriga, Carlos Martínez-Torró, et al.
Microbial Cell Factories (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top